Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by crow27on Feb 18, 2021 8:28pm
314 Views
Post# 32605856

Phase 3

Phase 3So they say when a Bio firm enters phase 3 trials the market cap of that company is in that 600 million dollar range. That is where ATB is heading.
So at 50 million shares (rough figure) that would put our SP at around $12.00
That is not counting any other parnership deals along the way. We already made one great partnership ship deal last week and very likely more are in the wind. So we could see a $12 to $15 share price. That's just the price of being at the dance running your trials.
Not a worry now about can we afford to go there as we are golden with cash.
I think Nasdaq would really love this company as their product is just what the DR ordered. These Bio followers know how to promote a stock.
I had a bio stock many years ago that ran from $4.00 to $31.00 in one day. Opened at $4.00 ran up all morning to $31 and then ran back down and closed at $8.00. This was on the Nasdaq.

You can see the bargain this stock is now especially now that we have totally derisked. Basically we have next to no risk. I believe Dan will make this all much clearer with the next NR's.
$6.17 is a solid buy!!  I think also we climb back to the $7's quickly.


<< Previous
Bullboard Posts
Next >>